Alexion announces outcomes of eculizumab two open-label Phase 2 research for aHUS treatment Alexion Pharmaceuticals, Inc Vegetarians and vegans . AHUS is an ultra-rare, persistent and life-threatening disease where uncontrolled complement activation causes bloodstream clots in small blood vessels through the entire body resulting in stroke, heart strike, kidney death and failure. 60 % of individuals with aHUS require dialysis Approximately, a kidney transplant or die within a complete year of diagnosis. Abstracts summarizing these interim data have been posted on the web site of the American Society of Nephrology at These two trials are ongoing and data will end up being shown at the ASN annual meeting held November 18 – 21 in Denver, Colorado.